Prosus invests $460 million in Alan, valuing health tech at $6.3 billion

Alan, the French health tech company that combines insurance, prevention and care into a single platform, has secured a $460 million investment from Prosus that values the startup at $6.3 billion — one of the largest ever in European digital health.

Dutch investment firm Prosus has invested $460 million (€400 million) into Alan, the Paris-based health tech company, in a round that also included existing backers Teachers' Venture Growth and Index Ventures alongside new investor Dara Holdings. The investment consists of both primary and secondary equity, Prosus said Wednesday.

"Healthcare presents one of the most significant global opportunities for AI-led transformation," said Fahd Beg, Head of Investments at Prosus Group. "Alan has built something unique: an integrated platform where insurance, prevention and care delivery reinforce each other, creating an exceptional healthcare experience for consumers and outstanding platform engagement."

Alan reached more than €800 million ($909 million) in annual recurring revenue as of the first quarter of 2026, up 53% year-over-year, and is already profitable in France, its largest market. The company serves more than 1.1 million individuals across 37,000 businesses in France, Spain, Belgium and Canada, with a team of about 850 employees. Its operating leverage — scaling revenue with limited headcount growth — reflects the efficiency of its AI-native model.

The deal underscores a broader shift in European health tech, where investors are betting that AI can transform a fragmented, cost-heavy system. Alan's model of "prevention insurance" — intervening before health problems escalate rather than only covering treatment — positions it at the intersection of insurance technology and primary care, two sectors that have historically operated separately. For Prosus, the investment extends its consumer ecosystem into healthcare, supporting what the firm calls its "life assistant" strategy.

How Alan plans to use the capital

The funding will accelerate Alan's international expansion into large markets where Prosus has a strong presence, as well as its AI-led product development. Alan will gain access to Prosus' Large Commerce Model, a proprietary AI system that Prosus has built across its portfolio of e-commerce and consumer technology businesses. The transaction is subject to regulatory approvals from French financial authorities.

Alan's co-founder and CEO, Jean-Charles Samuelian-Werve, said the company is still in the early stages of its ambition. "Health can't wait, not for symptoms to get worse, not for a six-month appointment, not for the system to catch up," he said. "We believe great health is a universal right, and that prevention should be too."

What the deal means for European health tech

The $6.3 billion valuation places Alan among the most valuable private health technology companies in Europe, a sector that has historically lagged behind U.S. peers in venture funding. The investment signals that large technology-focused investors like Prosus see health services as a scalable, AI-driven category rather than a regulated utility. Alan's ability to reach profitability in its home market while still growing at more than 50% annually provides a template that other European health tech startups may seek to replicate.

This article is for informational purposes only and does not constitute investment advice.